Cytosorbents (NASDAQ:CTSO) Coverage Initiated at StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of Cytosorbents (NASDAQ:CTSO) in a research note issued to investors on Thursday. The firm set a “hold” rating on the medical research company’s stock.

A number of other research firms have also recently commented on CTSO. B. Riley reaffirmed a “buy” rating and issued a $3.00 price target on shares of Cytosorbents in a report on Wednesday, May 15th. HC Wainwright reaffirmed a “neutral” rating and issued a $1.00 price target on shares of Cytosorbents in a report on Tuesday, May 7th.

Cytosorbents Price Performance

Cytosorbents stock opened at $0.70 on Thursday. Cytosorbents has a 52 week low of $0.70 and a 52 week high of $4.29. The company’s 50 day moving average price is $0.86 and its two-hundred day moving average price is $0.99. The company has a quick ratio of 1.21, a current ratio of 1.49 and a debt-to-equity ratio of 0.10. The stock has a market cap of $38.18 million, a P/E ratio of -1.19 and a beta of 0.61.

Cytosorbents (NASDAQ:CTSO) last posted its earnings results on Thursday, May 9th. The medical research company reported ($0.12) EPS for the quarter, hitting the consensus estimate of ($0.12). Cytosorbents had a negative net margin of 75.07% and a negative return on equity of 129.89%. The firm had revenue of $9.79 million for the quarter, compared to analysts’ expectations of $9.78 million. During the same quarter last year, the firm earned ($0.17) EPS. On average, equities analysts predict that Cytosorbents will post -0.36 earnings per share for the current year.

Institutional Investors Weigh In On Cytosorbents

A number of hedge funds have recently modified their holdings of the stock. Key Client Fiduciary Advisors LLC grew its stake in Cytosorbents by 188.0% in the 1st quarter. Key Client Fiduciary Advisors LLC now owns 34,557 shares of the medical research company’s stock valued at $33,000 after buying an additional 22,557 shares in the last quarter. Raymond James & Associates purchased a new position in Cytosorbents in the 4th quarter valued at approximately $56,000. CM Management LLC grew its stake in Cytosorbents by 98.8% in the 1st quarter. CM Management LLC now owns 825,000 shares of the medical research company’s stock valued at $784,000 after buying an additional 410,000 shares in the last quarter. Sargent Investment Group LLC grew its stake in Cytosorbents by 4.1% in the 4th quarter. Sargent Investment Group LLC now owns 1,308,747 shares of the medical research company’s stock valued at $1,453,000 after buying an additional 51,699 shares in the last quarter. Finally, Neuberger Berman Group LLC grew its stake in Cytosorbents by 19.9% in the 4th quarter. Neuberger Berman Group LLC now owns 1,801,799 shares of the medical research company’s stock valued at $1,997,000 after buying an additional 299,103 shares in the last quarter. Institutional investors own 32.87% of the company’s stock.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.